Dr. Paolo Tarantino dives into the latest ADC-driven shifts from ESMO 2025 across breast cancer subtypes—reviewing TROPION-Breast02, ASCENT-03, DESTINY-Breast11, and DESTINY-Breast05—and shares what should be the overall learning from this year’s ESMO.
